Pseudomonas Aeruginosa Infection Treatment Market Report 2024: Strategies And Recent Developments | AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co Inc., Janssen Pharmaceutica NV, Pfizer Inc., Lupin Limited, AstraZeneca plc, Bristol Myers Squ

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2629

The Business Research Company offers in-depth market insights through Pseudomonas Aeruginosa Infection Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The pseudomonas aeruginosa infection treatment market size has grown strongly in recent years. It will grow from $2.28 billion in 2023 to $2.48 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rising incidence of nosocomial infections, growing antibiotic resistance concerns, increased healthcare expenditure, expansion of hospital and healthcare facilities, focus on early diagnosis and intervention..

The pseudomonas aeruginosa infection treatment market size is expected to see strong growth in the next few years. It will grow to $3.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increased research on antimicrobial peptides, focus on therapeutic efficacy and safety, rise in cases of multidrug-resistant p. aeruginosa, patient-centric approaches in treatment development, regulatory incentives.. Major trends in the forecast period include combination therapies, advancements in drug delivery, point-of-care diagnostics, integration of genomic data in treatment strategies, global collaboration in antibiotic research..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=9174&type=smp

Market Segmentation:
The pseudomonas aeruginosa infection treatment market covered in this report is segmented -

1) By Medication: Monotherapy, Combination Therapy
2) By Drug Class: Aminoglycoside, Cephalosporin, Carbapenem, Monobactum, Other Drug Classess
3) By Route Of Administration: Nasal, Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Major Driver - Pseudomonas Aeruginosa Infection Market Growth Driven By Rising Co-Morbidities
The increasing incidence of co-morbidities such as pneumonia, cystic fibrosis, urinary tract infection, and bloodstream infection is expected to propel the growth of the pseudomonas aeruginosa infection treatment market going forward. Comorbidity refers to any concurrent medical condition. Comorbidities are frequently chronic conditions that can affect either physical or mental health. For instance, in August 2022, according to an article published by the National Library of Medicine, a US-based biomedical library and the center of computational biology and biomedical informatics, the incidence rate of community-acquired pneumonia in the US is 24.8 instances per 10,000 adult population annually, with rates rising with advancing age. Pneumonia is the eighth most common cause of death and the leading infectious cause of death. Patients hospitalized in the intensive care unit have a death rate as high as 23%. Therefore, the increasing incidence of co-morbidities such as pneumonia, cystic fibrosis, urinary tract infection, and bloodstream infection is driving the growth of the pseudomonas aeruginosa infection treatment market.

Competitive Landscape:
Major companies operating in the pseudomonas aeruginosa infection treatment market report are AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co Inc., Janssen Pharmaceutica NV, Pfizer Inc., Lupin Limited, AstraZeneca plc, Bristol Myers Squibb Company, Gilead Sciences Inc., Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, Bayer AG, Aradigm Corporation, AmpliPhi Biosciences Corporation, Humanigen Inc., Johnson & Johnson, Lupin Pharmaceuticals Inc., Baxter International Inc., Neopharma LLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Astellas Pharma Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Cipla Inc., Hikma Pharmaceuticals plc, Zydus Cadila Healthcare Limited, Wockhardt Ltd., Akorn Inc., Mayne Pharma Group Limited, Endo International plc, Glenmark Pharmaceuticals Ltd., Lannett Company Inc., Perrigo Company plc, Amneal Pharmaceuticals LLC, Apotex Inc., Athenex Inc., Bausch Health Companies Inc., Biocon Ltd., Cadila Healthcare Ltd. .

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/pseudomonas-aeruginosa-infection-treatment-global-market-report

Top Trend - Technological Advancements In The Pseudomonas Aeruginosa Infection Treatment Market
Technological advancements are the key trend gaining popularity in the pseudomonas aeruginosa infection treatment market. Major companies operating in the market are developing novel vaccines, biologics such as antimicrobial peptides and therapeutic antibodies, virulence inhibitors, antimicrobials with novel targets, antibody-drug conjugates, resistance inhibitor-antibiotic or antibiotic-potentiator combinations, and bacteriophages or phage-derived lysins to sustain their position in the market. For instance, in April 2021, Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, a US-based global non-profit organization that supports antimicrobial research, is funding Phico Therapeutics, a UK-based biotechnology company, to develop a unique intravenous-designed bacteriophage medication to treat ventilator-associated pneumonia brought on by Pseudomonas aeruginosa. With its revolutionary SASPject technology, Phico can precisely target the P. aeruginosa bacteria and inactivate their DNA, preventing them from proliferating and spreading. This is done by using engineered bacterial viruses (bacteriophages) in conjunction with antibacterial small acid-soluble spore proteins (SASPs).

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Pseudomonas Aeruginosa Infection Treatment Market Characteristics
3. Pseudomonas Aeruginosa Infection Treatment Market Trends And Strategies
4. Pseudomonas Aeruginosa Infection Treatment Market - Macro Economic Scenario
5. Pseudomonas Aeruginosa Infection Treatment Market Size And Growth
…..
27. Pseudomonas Aeruginosa Infection Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.